Transcatheter Technologies Will Report One-Year Follow-up Results for Study of Its ‘Truly Repositionable’ Trinity TAVI System at ‘TCT 2014’ in Washington, DC

“Speaking as a physician who has used various TAVI systems and has experienced their flaws, I therefore know firsthand why our third-generation Trinity system could be a game-changer for TAVI.”

Wolfgang Goetz, MD, CEO

TCT 2014

REGENSBURG, Germany--()--Transcatheter Technologies GmbH, an emerging medical device company that is developing a third-generation transcatheter aortic valve implantation (TAVI) system—Trinity—will disclose the successful one-year follow-up results of its Trinity TAVI system that is designed to be the world’s first ‘truly repositionable’ and best TAVI system.

The clinical data will be presented during ‘TCT 2014’ on Monday, Sept. 15, 4:25 p.m. ET, at the Walter E. Washington Convention Center, Level 2, Room 202A/B, “Early Stage New TAVR Systems: Trinity Valve – Technology Review, Clinical Results, and Case Examples.”

“The one-year follow-up clinical results are impressive,” said principal investigator Prof. Dr. Christian Hengstenberg, a cardiologist at the German Heart Center, Munich, Germany, who will present the Trinity data at TCT 2014. “Unlike currently marketed TAVI systems, the Trinity aortic valve can be positioned precisely or even repositioned after full implantation in a safe manner. Equally important, Trinity’s unique sealing cuff continues to provide outstanding results without PVL, a well-known and frequent complication of TAVI. Furthermore, the risk of atrio-ventricular (AV) block has been essentially alleviated because of the supra-annular positioning of the Trinity valve.”

“An unforgiving limitation of currently marketed TAVI systems is that they can not be repositioned once fully implanted. Conversely, Trinity is designed to correct this life-threatening imperfection and therein abate the unwelcome side effects of PVL and AV block,” said Wolfgang Goetz, M.D., Ph.D., CEO, a cardiac surgeon who has used many of the currently marketed TAVI systems. “The huge advantage of Trinity is that once the valve is completely expanded and anchored above the annulus, you are then able to entirely evaluate the valve’s function, unlike currently marketed TAVI systems, to decide if it needs to be repositioned, retrieved, or kept in the same position. This feature is absolutely unique to Trinity and the reason why we have positioned Trinity as the Third-Generation TAVI System.”

About Transcatheter Technologies GmbH

Transcatheter Technologies GmbH is a privately held medical device company headquartered in Regensburg, Germany. Its Trinity aortic valve prosthesis is comprised of a bovine pericardium valve with porcine pericardium-sealing cuff that is mounted on a self-expanding Nitinol frame. The Trinity aortic valve prosthesis is pre-mounted on a detachable catheter tip. Trinity’s unique features enable controlled positioning and true repositioning without foreshortening. The valve prosthesis is protected during folding of the stent. This Zero Pressure CrimpingTM is expected to improve valve durability and broaden the application of transcatheter valve implantations across a larger patient population.

Disclaimer

All information contained in this document derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this document or its contents. This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. International investors acknowledge risks in connection with political and economic uncertainties in foreign countries as well as currency risks. Persons who are in possession of this document are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends, or circumstances after the date of this press release.

Contacts

Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1 508-359-4005, x108
or
Corporate Contact:
Transcatheter Technologies GmbH
Wolfgang Goetz, MD, PhD, CEO, +49 170-630-9920
wg@transcatheter-technologies.com

Release Summary

Transcatheter Technologies will report one-year follow-up results for study of its ‘truly repositionable’ Trinity TAVI system at ‘TCT 2014’ in Washington, DC

Contacts

Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1 508-359-4005, x108
or
Corporate Contact:
Transcatheter Technologies GmbH
Wolfgang Goetz, MD, PhD, CEO, +49 170-630-9920
wg@transcatheter-technologies.com